PDA-TC is an education pamphlet which helps patient become involved in decision-making by providing information about the treatment options and their outcomes and by clarifying personal values. This pilot study of PDA-TC will involve a cross-sectional prospective observational pilot study.
The thyroid cancer incidence rates have increased by more than two-and-half times (175%) in the UK since early 1990s. The surge of differentiated thyroid cancer (DTC) has been suggested to be at least partly owing to overdiagnosis. Due to the widespread use of advanced imaging and increased pathological scrutiny of thyroid specimens, the majority of these cases are small/early low-risk cancers. Around 72% of thyroid cancer cases in the UK are in females and the disease is often diagnosed at a younger age (30 to 50), compared to other adult cancers. Until 2015, the standard of care for DTC has been a 'one size fits all' approach of total thyroidectomy (TT) for more than 1 cm DTC which may be followed with adjuvant radioactive iodine ablation. This treatment has afforded excellent overall survival rate (98-99% at 10-year) and a low recurrence rate (2-8% at 7-year). However, this survival benefit comes at the price of life-long hormone replacement therapy and increased risk of post-operative complication such as vocal cord paralysis and hypoparathyroidism. These negative ramifications of TT have a huge implication on thyroid patient's physical and emotional functioning, their working and family life, and long-term quality of life (QoL).
In addition, a significant number of DTC cannot be confirmed with needle biopsy. Therefore, TT is often performed in two stages with diagnostic hemithyroidectomy (HT) of the main lobe first (to confirm the diagnosis) while the remain gland is excised at a later stage, subjecting patient to two operations. In response to widely published concerns about overdiagnosis and overtreatment, both the British Thyroid Association 2014 guideline and the American Thyroid Association 2015 guideline have endorsed hemithyroidectomy (HT) as an alternative treatment approach to TT for DTC. This is because TT does not appear to offer an overall survival advantage over HT. Although HT is generally better tolerated by patient, it carries a higher cancer recurrence rate when compared with TT. In the UK, many thyroid cancer multidisciplinary teams and surgeons have started to offer HT to low-risk DTC patients while other centres continue to recommend TT as the main treatment approach. A clear clinical equipoise therefore exists for managing low-risk thyroid cancer. When faced with this equipoise, where clinicians are not sure and data are still equivocal, it is even more difficult for patients to understand the issues and make a treatment choice that is best for their individual needs and priorities. Due to the excellent prognosis, there is an ever-increasing pool of cancer-survivors in whom maintaining a good long-term QoL has become an integral part of their cancer care. Unfortunately, studies have shown that thyroid cancer survivors have a reduced QoL that is similar to or worse than those with more aggressive malignancies, such as breast or colon cancer. A recent National Patient Survey showed that the existing clinical equipoise has resulted in high level of confusion, dissatisfaction, and anxiety in patients with regards to treatment decision.
Shared Decision Making (SDM) is characterised by intentional and cooperative communication between patient and clinician in which knowledge, values, and preferences are shared and a process of common deliberation leads to a treatment decision. As the treatment decision for low-risk DTC is highly preference sensitive, SDM is even more relevant in thyroid cancer care to ensure that decisions made are consistent with each patient's preference. However, it can be difficult to achieve in standard clinical encounters because of the clinician's inability to establish patient values as well as patient's limited knowledge, unrealistic outcome expectations, and decisional conflict. As evidenced by a systematic review on the decision-making process in thyroid cancer management, many clinicians expressed difficulty in performing SDM as due to concerns with overwhelming patients with detailed information regarding disease and treatment options and struggled to find the right question to elicit patients' preference and value. Instead, the clinicians tailored treatment recommendation based on their perception of patient's level of fear, anxiety and risk tolerance, often without explicit discussion of patient's feelings. As a result, clinicians may be at risk of making recommendations biased by their own beliefs and values and the treatment received may not reflect patients' actual treatment goals.
Patient decision aids (PDA) are condition-specific decision-making tools that facilitate SDM by providing plain-language information about the potential risks (short- and long-term side effects), benefits, and uncertainties related to treatment, and information on how QoL and daily life could be affected. PDAs also help patients to clarify their values regarding options. PDAs can be in the format of web-page, pamphlet or video. Whilst PDAs have been developed for other cancers and diseases such as prostate cancer, breast cancer, diabetes mellitus and rheumatoid arthritis, to date there is no PDA for low-risk DTC. The investigators have developed a PDA for adult patients with low-risk DTC. Use of a PDA in low-risk DTC should increase patient's health knowledge, reduce uncertainty about which decision to make (decision conflict), improve decisional satisfaction, improve accuracy of risk perception of the outcome and help patient to make choices better matched to their personal values. In the long-term this will decrease patient's anxiety and distress, improve their physical and emotional functioning and their overall health related QOL.
